DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: PLAVIX

Summary for Tradename: PLAVIX

Patents:2
Applicants:1
NDAs:1
Suppliers: see list12
drug
patent expirations by year for
 PLAVIX

Pharmacology for Tradename: PLAVIX

Clinical Trials for: PLAVIX

Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.
Status: Completed Condition: Coronary Artery Disease

Clopidogrel Bioequivalence Study in Healthy Subjects
Status: Not yet recruiting Condition: Bioequivalence, AUC, Cmax, Pharmacokinetics

Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)
Status: Completed Condition: Acute Coronary Syndrome

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Status: Completed Condition: Healthy

Clopidogrel PGX Bench to Bedside
Status: Completed Condition: Metabolism of Clopidogrel

Clopidogrel Pharmacogenomics Project
Status: Completed Condition: Disease Susceptibility

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Status: Not yet recruiting Condition: CLOPIDOGREL, POOR METABOLISM of (Disorder)

Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel
Status: Completed Condition: Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel; Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Status: Completed Condition: Stable Coronary Artery Disease

Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
Status: Recruiting Condition: Antiplatelet Agents

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839Nov 17, 1997RXNo<disabled><disabled>
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839Nov 17, 1997RXNo<disabled><disabled>
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839Nov 17, 1997RXNo6,429,210*PED<disabled>Y<disabled>
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839Nov 17, 1997RXNo6,504,030*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PLAVIX

Drugname Dosage Strength RLD Submissiondate
clopidogrel bisulfateTablets300 mgPlavix3/4/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc